115 related articles for article (PubMed ID: 18783939)
21. External validation of an international multicenter study to predict survival in Korean patients with pT2N0M0 renal cell carcinoma.
Ku JH; Moon KC; Kwak C; Kim HH
Urology; 2009 Aug; 74(2):359-63. PubMed ID: 19501879
[TBL] [Abstract][Full Text] [Related]
22. Renal cell carcinoma metastatic to the stomach: single-centre experience and literature review.
Pollheimer MJ; Hinterleitner TA; Pollheimer VS; Schlemmer A; Langner C
BJU Int; 2008 Aug; 102(3):315-9. PubMed ID: 18336607
[TBL] [Abstract][Full Text] [Related]
23. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases.
Amin MB; Paner GP; Alvarado-Cabrero I; Young AN; Stricker HJ; Lyles RH; Moch H
Am J Surg Pathol; 2008 Dec; 32(12):1822-34. PubMed ID: 18813125
[TBL] [Abstract][Full Text] [Related]
24. EORTC-GU group expert opinion on metastatic renal cell cancer.
de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
[TBL] [Abstract][Full Text] [Related]
25. Validation of the current prognostic models for nonmetastatic renal cell carcinoma after nephrectomy in Chinese population: a 15-year single center experience.
Liu Z; Lv J; Ding K; Fu Q; Cao Q; Wang F
Int J Urol; 2009 Mar; 16(3):268-73. PubMed ID: 19087209
[TBL] [Abstract][Full Text] [Related]
26. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib.
Trask PC; Bushmakin AG; Cappelleri JC; Bycott P; Liau K; Kim S
Acta Oncol; 2008; 47(5):843-51. PubMed ID: 18568482
[TBL] [Abstract][Full Text] [Related]
27. Treatment of metastatic renal cell carcinoma.
Reeves DJ; Liu CY
Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
[TBL] [Abstract][Full Text] [Related]
28. Preoperative prognostic nomogram (probability table) for renal cell carcinoma based on TNM classification.
Kanao K; Mizuno R; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Nakashima J; Oya M
J Urol; 2009 Feb; 181(2):480-5; discussion 485. PubMed ID: 19100568
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of adjuvant interferon-alpha therapy following curative resection in renal cell carcinoma: before the molecular targeting therapy era.
Kai F; Takayama T; Sugiyama T; Furuse H; Mugiya S; Ozono S
Jpn J Clin Oncol; 2009 May; 39(5):310-4. PubMed ID: 19363055
[TBL] [Abstract][Full Text] [Related]
30. Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study.
Capitanio U; Zini L; Perrotte P; Shariat SF; Jeldres C; Arjane P; Pharand D; Widmer H; Péloquin F; Montorsi F; Patard JJ; Karakiewicz PI
Urology; 2008 Nov; 72(5):1090-5. PubMed ID: 18799207
[TBL] [Abstract][Full Text] [Related]
31. Renal cell cancer stage migration: analysis of the National Cancer Data Base.
Kane CJ; Mallin K; Ritchey J; Cooperberg MR; Carroll PR
Cancer; 2008 Jul; 113(1):78-83. PubMed ID: 18491376
[TBL] [Abstract][Full Text] [Related]
32. Sociodemographic factors associated with nephrectomy in patients with metastatic renal cell carcinoma.
Hellenthal NJ; Chamie K; Ramirez ML; deVere White RW
J Urol; 2009 Mar; 181(3):1013-8; discussion 1018-9. PubMed ID: 19150554
[TBL] [Abstract][Full Text] [Related]
33. Stage-specific effect of nodal metastases on survival in patients with non-metastatic renal cell carcinoma.
Capitanio U; Jeldres C; Patard JJ; Perrotte P; Zini L; de La Taille A; Ficarra V; Cindolo L; Bensalah K; Artibani W; Tostain J; Valeri A; Zigeuner R; Méjean A; Descotes JL; Lechevallier E; Mulders PF; Lang H; Jacqmin D; Karakiewicz PI
BJU Int; 2009 Jan; 103(1):33-7. PubMed ID: 18990161
[TBL] [Abstract][Full Text] [Related]
34. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
[TBL] [Abstract][Full Text] [Related]
35. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
36. Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma.
Hara W; Tran P; Li G; Su Z; Puataweepong P; Adler JR; Soltys SG; Chang SD; Gibbs IC
Neurosurgery; 2009 Feb; 64(2 Suppl):A26-32. PubMed ID: 19165071
[TBL] [Abstract][Full Text] [Related]
37. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma.
Klatte T; Rao PN; de Martino M; LaRochelle J; Shuch B; Zomorodian N; Said J; Kabbinavar FF; Belldegrun AS; Pantuck AJ
J Clin Oncol; 2009 Feb; 27(5):746-53. PubMed ID: 19124809
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting.
Bregni M; Bernardi M; Servida P; Pescarollo A; Crocchiolo R; Treppiedi E; Corradini P; Ciceri F; Peccatori J
Bone Marrow Transplant; 2009 Aug; 44(4):237-42. PubMed ID: 19234510
[TBL] [Abstract][Full Text] [Related]
39. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.
Klatte T; Seligson DB; LaRochelle J; Shuch B; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Pantuck AJ; Belldegrun AS
Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):894-900. PubMed ID: 19240241
[TBL] [Abstract][Full Text] [Related]
40. Impact of several histopathological prognosticators and local tumour extension on oncological outcome in pT3b/c N0M0 renal cell carcinoma.
Roos FC; Weirich J; Victor A; Elsässer A; Brenner W; Biesterfeld S; Hampel C; Thüroff JW
BJU Int; 2009 Aug; 104(4):461-9. PubMed ID: 19338563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
